The graft is available in both a putty and strip configuration and Orthofix designed it to provide superior bone-forming capabilities with handling characteristics for a wide range of spine and orthopedic procedural applications.
“Using the same disciplined R&D approach we have historically taken with our internally processed demineralized bone matrix solutions, we created a product that challenges the performance expectations of typical synthetic bone graft substitutes,” said Orthofix Chief Scientific Officer Frank Vizesi. “OsteoCove is another prime example of leveraging our strengths in product development in combination with our vertically integrated manufacturing expertise.”
OsteoCove is made of biphasic ceramic granule that is comprised of β-tricalcium phosphate (ß-TCP) and hydroxyapatite (HA) combined with type-I bovine collagen. The topography is designed to elicit a bone-forming response. The company said the specialized surface chemistry and microporosity are shown to promote superior bone formation when compared to other commercially available advanced synthetic grafts.
“Orthofix is a leader in both the demineralized bone matrices (DBM) and cellular allograft markets, and the launch of OsteoCove significantly strengthens our biologics portfolio and builds on our mission to deliver best-in-class products in every major bone grafting category,” Orthofix President of Global Biologics Tyler Lipshultz said. “With the introduction of OsteoCove, we expect strong growth in this large market segment as we continue to deliver on our commitment to provide surgeons a comprehensive offering of biologic solutions to meet the needs of their patients.”
